Find Funding Opportunities

Adding NINDS-specific language.

This notice is to clarify that onlyBasic Experimental Studies Involving Humans (BESH) clinical trials are withinscope of the above NOFOs (PAR-25-020, PAR-25-055, PAR-24-098, and PAR-24-096). BESH are prospective basic science studies involving human participants (also see NOT-OD-18-212). These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. The types of studies that applicants should submit in response to these NOFOs include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind.

NINDS is joining for BRAIN.

The purpose of this Notice is to update the Eligible Individuals (Program Director/Principal Investigator section). This NOFO is only open to individuals that are citizens or non-citizen nationals of the United States or have been lawfully admitted for permanent residence to the United States of America.

In April 2021 and September 2021, NIH began providing childcare cost support, respectively to recipients of full-time NRSA fellowships and training grants in recognition that the high cost of childcare impacts graduate student and postdoctoral scholar ability to successfully complete their training and fully participate in the extramural research workforce (NOT-OD-21-074; NOT-OD-21-177; NOT-OD-24-116). Beginning in FY25, NIH will begin providing childcare cost support to individuals supported as full-time recipients of Predoctoral to Postdoctoral Fellow Transition Award (F99/K00) programs during the F99 phase of the award.

This Notice supersedes NOT-OD-21-070 - Notice of Special Interest (NOSI): Availability of Administrative Supplements for Childcare Costs for Ruth L. Kirschstein National Research Service Award (NRSA) and Individual Fellows and NOT-OD-21-075 - Notice of Correction to Application and Submission Information for NOSI: Availability of Administrative Supplements for Childcare Costs for Ruth L. Kirschstein National Research Service Award (NRSA) Individual Fellows (NOT-OD-21-070). In accordance with - NOT-OD-24-116 and ongoing efforts to support family-friendly work environments for the NIH-supported workforce, this Notice of Special Interest requests applications for administrative supplements to support childcare costs on NIH-supported F30, F31, F32 and F99 fellowship awards.

Due to the growing cost of individual grant applications and reduced use of the modular budget format, NINDS is faced with a challenging budgetary landscape. To maintain support for as many investigators as possible in this current environment requires careful management of research projects with large budgets. Effective immediately, NINDS will establish a more stringent payline for all grants applications requesting $500,000 or more in direct costs in any year (excluding consortium F&A) submitted in response to PAR-22-242 and PAR-22-243 Notices of Funding Opportunities (NOFOs) and their reissues.

Removing PEDP as it is not a responsive criteria.

This Announcement solicits applications for the early-stage development of therapeutics to mitigate the adverse health effects resulting from toxic chemical exposure. Chemical threats are toxic compounds that could be used in a terrorist attack or accidentally released from industrial production, storage or shipping. They include specific chemical warfare agents, toxic industrial chemicals, pesticides, and pharmaceutical-based agents. The overall scope of this solicitation includes validation of therapeutic targets and preclinical characterization of lead compounds. The UG3 phase of this announcement supports target validation and characterization of initial lead compound(s); UH3 phase activities include candidate optimization and in vivo demonstration of activity and efficacy in relevant post-exposure models. At the conclusion of the overall UG3/UH3 funding period, projects are expected to deliver at least one well-characterized therapeutic candidate.

Technical Assistance Webinars for RFA-NS-25-024 Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required)